Abstract
Background: CD70 is a tumor necrosis family member that is expressed on a broad spectrum of hematological malignancies including multiple myeloma, non-Hodgkin's lymphomas and Hodgkin's disease. In contrast to other immunotherapy targets such as CD19, CD20, or CD33, which are widely expressed in the hematopoietic system, CD70 expression is restricted to a subset of activated B and T cells, reducing potential ‘collateral damage’ when targeted by immunotherapy. Preclinical studies in animal models using monoclonal antibodies have validated CD70 as an immunotherapeutic target and the aim of this study was to generate CD70-specific T cells for adoptive immunotherapy approaches.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
